About this trial
As infection control improves and circulation stabilizes, treatment de-escalation of septic shock begins, accompanied by fluid redistribution from interstitial spaces to the vasculature, increasing cardiac volume load. Synthetic recombinant human BNP (rh-BNP) plays a role in inducing vasodilation, particularly in the venous system, alleviating cardiac congestion, and enhancing natriuresis and diuresis. Thus the investigators designed a single-center, prospective physiological study to evaluate the efficacy of standard rh-BNP infusion in reducing venous return and enhancing fluid removal, with a secondary objective of assessing the maintenance of perfusion pressure and tissue perfusion.
Eligibility criteria
Qualifiers
Age >18 years.
Fulfilling the Sepsis-3 definition of septic shock at initial stage.
Hemodynamic stability achieved after adequate initial resuscitation and individualized hemodynamic optimization.
Controlled infection source with 48-hour trend of improving temperature, white blood cell count, and procalcitonin.
Disqualifiers
Pregnancy or lactation.
Arrhythmia.
Advanced renal dysfunction (Acute Kidney Injury [AKI] stage 3 or Chronic Kidney Disease [CKD] stage 3b or higher) based on Kidney Disease: Improving Global Outcomes (KDIGO) criteria.
Inadequate ultrasound window preventing acquisition of diagnostic-quality images.
Trial design
Treatments tested in this trial
- Lyophilized Recombinant Human Brain Natriuretic Peptide
Treatment groups
Locations
Sponsors and collaborators
Sichuan Provincial People's Hospital
Lead sponsor
Tibet Kangzhe Pharmaceutical Development Co., Ltd
Collaborator